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Antitumor activityAbstract The synthesis of different series of 6-iodo-2-phenoxymethyl 3-substituted quinazolin-
4(3H)-ones 5–17 is described. The structures of the newly synthesized compounds have been con-
ﬁrmed on the basis of elemental analyses, IR, 1H NMR and mass spectral data. Preliminary testing
for the in vitro antitumor activity of the synthesized compounds against MCF-7 breast cell line was
carried out using Doxorubicin (IC50: 5.46 lmol/ml) as a reference drug. Compound 5b exhibited a
remarkable antitumor activity (IC50: 5.49 lmol/ml) almost similar to that expressed by the reference
drug, whereas compounds 7d, 12b and 6c (IC50: 6.23, 6.55 and 6.80 lmol/ml, respectively) showed a
considerable activity.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
Cancer is continuing to be a major health problem in develop-
ing as well as undeveloped countries.1,2 Although major ad-
vances have been made in the chemotherapeutic management
of some patients, the continuous search for discovering new
anticancer agents remains important.3
Quinazolinone is a heterocyclic compound that occupies a
distinct and unique place in the ﬁeld of medicinal chemistry.
It has gained an importance as antimicrobial,4 anti-inﬂamma-
tory,5 anticonvulsant,6 analgesic7 and anticancer agents.8–1075600699; fax: +20 23628246.
l.com (H.H. Georgey).
aculty of Pharmacy, Cairo
g by Elsevier
ng by Elsevier B.V. on behalf of F
://dx.doi.org/10.1016/j.bfopcu.201This broad spectrum of activities has been further facilitated
by the synthetic versatility of quinazolinones which allows
the generation of a large number of structurally diverse
derivatives.11
Interest in quinazolinones as anticancer agents has further
increased since the discovery of raltitrexed A and thymitaq
B.12
Additionally, some 2,3-disubstituted quinazolin-4(3H)-one
C13 and 2,3,6-trisubstituted quinazolin-4(3H)-one D12 are re-
ported to exhibit a good anticancer activity.
Accordingly, as a part of our ongoing effort to further
extend the structure activity relationship study in the ﬁeld of
quinazolinones, we embarked on a program to synthesize
6-iodo-2-phenoxymethyl-3-substituted quinazolin-4(3H)-one
derivatives as experimental anticancer agents.
The 3-substituents were designed to be hybridized with
some biologically active moieties including sulfonamides,14
un/substituted benzylideneamino,15 imidazolo,16 thiazolo,17
oxadiazolo18 and thiadiazolo19 nuclei that were reported to en-
hance the antitumor activity.aculty of Pharmacy, Cairo University.
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274 S.E. Abbas et al.The preparation of such targets proceeds via the intermedi-
ate 3-amino-6-iodo-2-(phenoxymethyl)quinazolin-4(3H)-one
(4) and the synthesis of the target compounds is depicted in
Scheme 1–3.
2. Chemistry
Reaction of 2-phenoxyacetyl chloride (1) with 5-iodo methyl
anthranilate (2) in dry benzene afforded methyl 5-iodo-2-(2-
phenoxyacetamido)benzoate (3). The structure of 3 was
conﬁrmed by spectroscopic (IR, 1H NMR, MS) as well as ele-
mental analysis data. The IR spectrum revealed two strong
bands at m= 1681 and 1708 cm1 region assigned for the car-
bonyl of the amide and the ester, respectively. 1H NMR spec-
trum showed the NH proton as a singlet signal at d= 12.07
(disappeared upon deuteration). Reaction of 3 with hydrazine
hydrate in reﬂuxing n-butanol gave 3-amino-6-iodo-2-(phen-
oxymethyl)quinazolin-4(3H)-one (4), the key intermediate in
Scheme 1. The IR spectrum revealed one carbonyl stretching
vibration band at m = 1670 cm1 region and lacked the other
band assigned for the second carbonyl group at m = 1701 cm
1 conﬁrming the cyclized structure. In addition, 1H NMR
spectrum demonstrated the amino group protons as a singlet
signal at d= 5.75 (disappeared upon deuteration) in addition
to the absence of the methyl group protons at d= 3.95
(Scheme 1).
Reaction of 4 with acetic anhydride or various acid anhy-
drides ‘‘namely maleic and phthalic’’ in reﬂuxing glacial acetic
acid afforded the corresponding 3-substituted-6-iodo-2-(phen-
oxymethyl)quinazolin-4(3H)-one 5a–c. The IR spectrum of 5a
showed an additional carbonyl stretching vibration band at
m= 1701 cm1, while 5b,c spectra revealed the presence of
two bands attributed to the two carbonyl groups at
m= 1701–1747 cm1 region and the disappearance of the ami-
no group protons signal at d= 5.75 in 1H NMR spectra.
Meanwhile, condensation of 4 with aromatic aldehydes
(benzaldehyde, 4-chlorobenzldehyde, anisaldehyde and 4-ﬂuo-
robenzaldehyde) in reﬂuxing glacial acetic acid produced thecorresponding Schiff’s bases 6a–d. The IR spectra of 6a–d
illustrated the disappearance of the NH2 bands at m= 3329,
3248 cm1 and 1H NMR spectra displayed the azomethine
proton as a sharp singlet signal at d= 8.96–9.12 region. Addi-
tionally, reduction of 6a–d with sodium borohydride in abso-
lute ethanol afforded benzylamino derivatives 7a–d. 1H
NMR spectra lacked the azomethine proton signal and re-
vealed the appearance of NH singlet signal at d= 4.20–5.14
region (disappeared upon deuteration) in addition to another
singlet signal at d= 3.18–4.12 region assigned for CH2 pro-
tons. Moreover, reaction of 4 with 4-(4-substituted benzyli-
dene)-2-phenyloxazol-5(4H)-one 8a,b in reﬂuxing glacial
acetic acid, in the presence of anhydrous sodium acetate affor-
ded benzylidene imidazolone derivatives 9a,b. Their structures
were deduced by the disappearance of NH2 bands and signals
in the IR and 1H NMR spectra, in addition to the presence of a
singlet signal at d= 9.95 and 9.96 corresponding to the ole-
ﬁnic proton in 1H NMR spectra (Scheme 1).
Acylation of 4 with chloroacetyl chloride in dimethyl-
formamide yielded chloroacetylamino derivative 10, the
key intermediate in Schemes 2 and 3. The latter upon reac-
tion with various primary amines ‘‘namely 2-amino-5-substi-
tuted oxa/thiadiazole and sulfonamide derivatives’’ in
reﬂuxing acetonitrile in the presence of anhydrous potas-
sium carbonate underwent aromatic nucleophilic substitu-
tion reaction and afforded 12a–c and 13a–c, respectively.
1H NMR spectra displayed D2O exchangeable NH protons
as a singlet signal ranging from d= 5.20–12.65 and the
mass spectra exhibited the parent molecular ion peaks con-
ﬁrming the structures (Scheme 2).
In addition, compound 10 was allowed to react with some
secondary amines ‘‘namely 4-substituted piperidines’’ in reﬂux-
ing acetonitrile in the presence of catalytic amount of triethyl-
amine, where the corresponding piperidinyl acetamido
derivatives 14a–c were obtained. 1H NMR spectra of 14a–c
showed the acetamido methylene protons shifted upﬁeld
(d= 3.21, 3.33, 3.38) relative to that of the precursor 10 which
appeared at d= 4.16, 4.30 region (Scheme 2).
O
Cl
O NH2
I
1
2
Dry benzene 3
N
N
NH2I
O
O
4
Hydrazine hydrate
n-butanol
N
N RI
O
O
N
N NI
O
O
R
N
N NI
O
N
O
O
R
N
N
H
NI
O
O
R
N
O
O
R
Acid anyhdrides
CH3COOH
CHOR
CH3COOH
NaBH4
C2H5OH
CH3COOH
5
6
7
9
8
5a; R= NHCOCH3
N
O
O
5b; R=
N
O
O
5c; R= 6c, 7c; R= F
6d, 7d; R= OCH3
8a, 9a; R= H
8b, 9b; R=Cl
6a, 7a; R= H
6b, 7b; R= Cl
NH
O O
COOCH3ICOOCH3
Scheme 1
Synthesis and antitumor activity of certain 2,3,6-trisubstituted quinazolin-4(3H)-one derivatives 275Cyclization of the chloroacetylamino moiety in compound
10 to produce thiazolone derivative 15 was achieved via reﬂux-
ing with ammonium thiocyanate in absolute ethanol. 1H NMR
spectrum exhibited the appearance of a singlet signal at
d= 4.08 assigned for CH2 protons of the thiazolone ring, to-
gether with another singlet signal at d= 12.45 attributed to
the NH proton (disappeared upon deuteration). 13C NMR
spectrum revealed three additional signals at 38.6, 158.1 and
159.2 attributed to the thiazolo CH2, C = N and CO, respec-
tively. Rigidiﬁcation of the chloroacetylamino derivative 10
was performed to produce the tricyclic derivatives 16 and 17.
This was accomplished by reﬂuxing 10 with ammonium acetate
in glacial acetic acid or with thiourea in absolute ethanol,where triazino 16 and tetrazino 17 derivatives were obtained,
respectively. 1H NMR spectrum of 16 exhibited the presence
of a singlet signal at d= 5.07 of CH2 protons of the triazinone
ring, in addition to a singlet signal at d= 12.65 attributed to
the NH proton (disappeared upon deuteration). 13C NMR
spectrum revealed a signal for the triazino CH2 at 40.6 and
another signal attributed to the triazino CO at 207.7 together
with the disappearance of C-4 signal of quinazolinone at 160.0.
1H NMR spectrum of 17 revealed the disappearance of the NH
proton signal at d= 8.99, in addition to the appearance of a
singlet signal at d= 2.08 assigned for CH2 protons of the
tetrazocinone ring and another singlet signal at d= 11.19
attributed to the two NH groups protons (disappeared upon
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276 S.E. Abbas et al.deuteration). 13C NMR spectrum exhibited three signals at
21.2, 170.2 and 171.0 assigned for the tetrazocino CH2, CO
and CS, respectively, and lacked C-4 signal of quinazolinone
at 160.0.
2.1. Experimental
Melting points are uncorrected and recorded on Stuart
SMP3 melting point apparatus. Elemental Microanalysis
was carried out at the Micro Analytical Center, Cairo
University or at The Regional Center for Mycology and
Biotechnology, Al-Azhar University. IR spectra (KBr) were
recorded on Shimadzu Infrared spectrophotometer. 1H
NMR and 13C NMR spectra were recorded on a Varian
MERCURY 300 (300 MHz) spectrometer, 13C, 70 MHz
NMR spectrometer, or Jeol-ECA500, 500 MHz Japan. Mass
Spectra were recorded using Shimadzu Gas Chromatograph
Mass spectrometer-Qp 2010 plus (Japan) or Jeol JMS-AX
500 mass spectrometer (Japan). The starting compounds
1,20 2,21 8a,b,22 and 11a–c23 were prepared according to the
previously reported procedures.2.1.1. Methyl 5-iodo-2-(2-phenoxyacetamido)benzoate (3)
2-Phenoxyacetylchloride (1) (10 mmol, 1.7 g) was added drop-
wise to the solution of 5-iodo methyl anthranilate (2)
(15 mmol, 4.1 g) in dry benzene. The reaction mixture was stir-
red overnight at room temperature and then ﬁltered. The ﬁl-
trate was successively washed with dilute hydrochloric acid
(3 · 20 ml), water, 10% sodium hydroxide (3 · 20 ml) and
ﬁnally water. The organic layer was ﬁltered over anhydrous so-
dium sulfate and evaporated under reduced pressure.
Colorless crystals from ethanol, mp 125–127 C, yield 80%.
IR: mmax/cm
1 3360 (NH), 1708 (C‚O ester), 1681 (C‚O
amide), 1573, 1516 (C‚C). 1H NMR (CDCl3): d 3.95 (s, 3H,
CH3), 4.63 (s, 2H, CH2), 7.02–8.62 (m, 8H, arom. H), 12.07
(s, 1H, D2O exchangeable NH). MS: m/z (%): 411 (M
+, 98),
136 (5), 76 (100). Anal. calcd. for C16H14INO4 (411.19): C,
46.74; H, 3.43; N, 3.41. Found: C, 46.81; H, 3.42; N, 3.53.
2.1.2. 3-Amino-6-iodo-2-(phenoxymethyl)quinazolin-4(3H)-
one (4)
A mixture of 3 (10 mmol, 4.1 g) and hydrazine hydrate 99%
(20 mmol, 1 g) in n-butanol (10 ml) was reﬂuxed for 8 h. The
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reduced pressure was collected, dried and crystallized from
benzene.
Colorless crystals, mp 159–160 C, yield 50%. IR: mmax/cm1
3329, 3248 (NH2), 1670 (C‚O), 1570, 1593 (C‚C).
1H NMR
(CDCl3): d 5.31 (s, 2H, CH2), 5.75 (s, 2H, D2O exchangeable
NH2), 6.92–8.40 (m, 8H, 5 arom. H + 3 quinazolinone H).
MS: m/z (%): 393 (M+, 57), 377 (75), 285 (9), 271 (100).
13C NMR (CDCl3): 68.2 (CH2), 91.9 (quinazolinyl C-6),
122.0 (quinazolinyl C-4a), 129.54 (quinazolinyl C-8), 135.2
(quinazolinyl C-5), 143.0 (quinazolinyl C-7), 145.6 (quinazoli-
nyl C-8a), 157.7 (quinazolinyl C-2), 159.3 (quinazolinyl C-4),
114.7, 121.8, 129.59, 151.9 (arom. C). Anal. calcd. for
C15H12IN3O2 (393.18): C, 45.82; H, 3.08; N, 10.69. Found:
C, 45.57; H, 2.92; N, 11.00.
2.1.3. General procedure for preparation of compounds 5a–c
A mixture of equimolar amounts of 4 and the appropriate acid
anhydride (10 mmol) in glacial acetic acid (20 ml) was reﬂuxed
for 3 h. The reaction mixture was poured onto ice-cold water
and the separated solid was collected, washed with water and
crystallized from ethanol affording the corresponding 5a–c.
In case of 5a, the reaction mixture was heated in acetic anhy-
dride (10 ml).
2.1.3.1. N-(6-Iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-
yl)acetamide (5a). Colorless crystals, mp 135–136 C, yield
80%. IR: mmax/cm
1 3421 (NH), 1701 br. (C‚O), 1589
(C‚C). 1H NMR (DMSO-d6): d 2.37 (s, 3H, CH3), 5.04 (s,
2H, CH2), 8.27 (s, 1H, D2O exchangeable NH), 7.00–8.47
(m, 8H, 5 arom. H + 3 quinazolinone H). MS: m/z (%): 435(M+, 9), 328 (17), 342 (100), 58 (6). Anal. calcd. for
C17H14IN3O3 (435.22): C, 46.92; H, 3.24; N, 9.66. Found: C,
47.24; H, 3.39; N, 9.81.
2.1.3.2. 1-(6-Iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-
yl)-1H-pyrrole-2,5-dione (5b). Colorless crystals, mp 119–
120 C, yield 60%. IR: mmax/cm1 1747, 1708 (C‚O), 1593
(C‚C). 1H NMR (DMSO-d6): d 5.08 (s, 2H, CH2), 6.90–
8.40 (m, 10H, 7 arom. H + 3 quinazolinone H). MS: m/z
(%): 473 (M+, 3), 393 (0.8), 377 (1), 54 (100). Anal. calcd.
for C19H12IN3O4 (473.22): C, 48.22; H, 2.56; N, 8.88. Found:
C, 48.40; H, 2.66; N, 9.14.
2.1.3.3. 2-(6-Iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-
yl)isoindoline-1,3-dione (5c). Pale yellow crystals, mp 270–
271 C, yield 80%. IR: mmax/cm1 1747, 1701 (C‚O),
1589 (C‚C). 1H NMR (DMSO-d6): d 5.17 (s, 2H, CH2),
6.90–8.10 (m, 12 H, 9 arom. H + 3 quinazolinone H).
MS: m/z (%): 523 (M+, 17), 446 (0.3), 160 (79), 76
(100). 13C NMR (DMSO-d6): 66.5 (CH2), 105.8 (quinazoli-
nyl C-6), 121.6 (quinazolinyl C-4a), 129.1 (quinazolinyl C-
8), 134.8 (quinazolinyl C-5), 144.8 (quinazolinyl C-7),
145.0 (quinazolinyl C-8a), 156.2 (quinazolinyl C-2), 162.5
(quinazolinyl C-4), 114.5, 121.4, 124.6, 129.3, 130.0, 136.0,
152.5 (arom. C), 163.6 (C‚O). Anal. calcd. for
C23H14IN3O4 (523.28): C, 52.79; H, 2.70; N, 8.03. Found:
C, 52.86; H, 2.79; N, 8.45.
2.1.4. General procedure for preparation of compounds 6a–d
A mixture of equimolar amounts of 4 and the corresponding
aromatic aldehyde (10 mmol) was reﬂuxed in glacial acetic acid
278 S.E. Abbas et al.(30 ml) for 8 h. The solid separated upon evaporating the reac-
tion mixture under reduced pressure was collected, washed
with water and crystallized from ethanol affording the corre-
sponding 6a–d.
2.1.4.1. 3-(Benzylideneamino)-6-iodo-2-(phenoxymethyl)qui-
nazolin-4(3H)-one (6a). Pale yellow crystals, mp 98–99 C,
yield 60%. IR: mmax/cm
1 1685 (C‚O), 1589, 1593 (C‚C).
1H NMR (DMSO-d6): d 5.27 (s, 2H, CH2), 6.89–8.46 (m,
13H, 10 arom. H + 3 quinazolinone H), 9.08 (s, IH,
N = CH). MS: m/z (%): 479 (M-2, 0.11), 285 (54), 105 (13),
77 (59), 46 (100). Anal. calcd. for C22H16IN3O2 (481.29): C,
54.90; H, 3.35; N,8.73. Found: C, 54.57; H, 2.50; N, 8.60.
2.1.4.2. 3-(4-Chlorobenzylideneamino)-6-iodo-2-(phenoxy-
methyl)quinazolin-4(3H)-one (6b). Colorless crystals, mp
205–206 C, yield 65%. IR: mmax/cm1 1689 (C‚O), 1550,
1555 (C‚C). 1H NMR (DMSO-d6): d 5.20 (s, 2H, CH2),
6.96–8.45 (m, 12H, 9 arom. H + 3 quinazolinone H), 9.12 (s,
IH, N = CH). MS: m/z (%): 517 (M+ 2, 0.14), 378 (7), 127
(25), 76 (71), 45 (100). 13C NMR (DMSO-d6): 66.7 (CH2),
92.5 (quinazolinyl C-6), 123.1 (quinazolinyl C-4a), 129.3 (qui-
nazolinyl C-8), 134.7 (quinazolinyl C-5), 142.8 (quinazolinyl
C-7), 144.8 (quinazolinyl C-8a), 156.1 (quinazolinyl C-2),
160.0 (quinazolinyl C-4), 114.8, 121.0, 129.1, 129.4, 130.3,
131.0, 137.3, 151.4 (arom. C), 167.7 (N = CH). Anal. calcd.
for C22H15ClIN3O2 (515.73): C, 51.24; H, 2.93; N, 8.15.
Found: C, 51.48; H, 2.93; N, 7.99.
2.1.4.3. 3-(4-Fluorobenzylideneamino)-6-iodo-2-(phenoxy-
methyl)quinazolin-4(3H)-one (6c). Pale yellow crystals, mp
158–159 C, yield 44%. IR: mmax/cm1 1666 (C‚O), 1593
(C‚C). 1H NMR (DMSO-d6): d 5.27 (s, 2H, CH2), 6.91–
8.70 (m, 12H, 9 arom. H + 3 quinazolinone H), 9.08 (s, IH,
N = CH). MS: m/z (%): 499 (M+, 0.48), 285 (11), 108 (51),
65 (100). Anal. calcd. for C22H15FIN3O2 (499.28): C, 52.92;
H, 3.03; N,8.42. Found: C, 53.19; H, 3.18; N, 8.70.
2.1.4.4. 6-Iodo-3-(4-methoxybenzylideneamino)-2-(phenoxy-
methyl)quinazolin-4(3H)-one (6d). Pale yellow crystals, mp
148–150 C, yield 60%. IR: mmax/cm1 1678 (C‚O), 1566
(C‚C). 1H NMR (CDCl3): d 3.90 (s, 3H, OCH3), 5.31 (s,
2H, CH2), 6.95–8.66 (m, 12H, 9 arom. H + 3 quinazolinone
H), 8.96 (s, IH, N = CH). MS: m/z (%): 511 (M+, 3), 285
(61), 135 (27), 121 (44), 90 (100). Anal. calcd. for
C23H18IN3O3 (511.31): C, 54.03; H, 3.55; N, 8.22. Found: C,
54.26; H, 3.62; N, 8.45.
2.1.5. General procedure for preparation of compounds 7a–d
A mixture of equimolar amounts of 6a–d and sodium borohy-
dride (10 mmol) was stirred overnight in absolute ethanol
(20 ml) at room temperature (20–25 C). The reaction mixture
was diluted with water and the solid separated was collected,
washed with water and crystallized from ethanol affording
the corresponding 7a–d.
2.1.5.1. 3-(Benzylamino)-6-iodo-2-(phenoxymethyl)quinazolin-
4(3H)-one (7a). Colorless crystals, mp 103–105 C, yield
40%. IR: mmax/cm
1 3282 (NH), 1639 (C‚O), 1600 (C‚C).1H NMR (DMSO-d6): d 4.12 (s, 2H, NH–CH2), 4.85 (s, 1H,
D2O exchangeable NH), 5.89 (s, 2H, OCH2), 6.51–7.84 (m,
13H, 10 arom. H + 3 quinazolinone H). MS: m/z (%): 486
(M+ 3, 0.92), 377 (11), 284 (1), 91 (100). Anal. calcd. for
C22H18IN3O2 (483.30): C, 54.67; H, 3.75; N,8.69. Found: C,
54.75; H, 3.81; N, 8.83.
2.1.5.2. 3-(4-Chlorobenzylamino)-6-iodo-2-(phenoxymethyl)
quinazolin-4(3H)-one (7b). Colorless crystals, mp 122–
124 C, yield 40%. IR: mmax/cm1 3275 (NH), 1639 (C‚O),
1600 (C‚C). 1H NMR (DMSO-d6): d 3.98 (s, 2H, NH–
CH2), 4.81 (s, 1H, D2O exchangeable NH), 5.02 (s, 2H,
OCH2), 6.01–7.83 (m, 12H, 9 arom. H + 3 quinazolinone
H). 13C NMR (DMSO-d6): 52.4 (NHCH2), 67.4 (OCH2),
77.3 (quinazolinyl C-6), 120.8 (quinazolinyl C-4a), 129.3 (qui-
nazolinyl C-8), 134.5 (quinazolinyl C-5), 140.7 (quinazolinyl
C-7), 141.0 (quinazolinyl C-8a), 157.9 (quinazolinyl C-2),
161.3 (quinazolinyl C-4), 114.4, 116.6, 128.0, 130.7, 131.7,
134.7, 137.1, 146.0 (arom. C). Anal. calcd. for C22H17ClIN3O2
(517.75): C, 51.04; H, 3.31; N,8.12. Found: C, 51.12; H, 3.43;
N, 8.36.
2.1.5.3. 3-(4-Fluorobenzylamino)-6-iodo-2-(phenoxymethyl)
quinazolin-4(3H)-one (7c). Pale yellow crystals, mp 167–
169 C, yield 85%. IR: mmax/cm1 3390 (NH), 1662 (C‚O),
1600 (C‚C). 1H NMR (DMSO-d6): d 4.20 (s, 2H, NH–
CH2), 5.14 (s, 1H, D2O exchangeable NH), 5.60 (s, 2H,
OCH2), 6.64–8.81 (m, 12H, arom. H + 3 quinazolinone H).
MS: m/z (%): 501 (M+, 43), 284 (40), 126 (25), 58 (100). Anal.
calcd. for C22H17FIN3O2 (501.29): C, 52.71; H, 3.42; N,8.38.
Found: C, 52.81; H, 3.52; N, 8.57.
2.1.5.4. 6-Iodo-3-(4-methoxybenzylamino)-2-(phenoxymethyl)
quinazolin-4(3H)-one (7d). Pale yellow crystals, mp 188–
189 C, yield 62%. IR: mmax/cm1 3492 (NH), 1681
(C‚O), 1600 (C‚C). 1H NMR (CDCl3): d 3.81 (s, 3H,
OCH3), 4.18 (s, 2H, NH–CH2), 4.20 (s, 1H, D2O exchange-
able NH), 5.23 (s, 2H, OCH2), 6.88–8.88 (m, 12H, 9 arom.
H + 3 quinazolinone H). Anal. calcd. for C23H20IN3O3
(513.33): C, 53.81; H, 3.93; N,8.19. Found: C, 53.94; H,
3.98; N, 8.42.
2.1.6. General procedure for preparation of compounds 9a–d
Amixture of equimolar amounts of 4 and 4-(4-substituted ben-
zylidene)-2-phenyloxazol-5(4H)-one 8a,b (10 mmol) in glacial
acetic acid (20 ml) containing anhydrous sodium acetate
(40 mmol, 3.2 g), was reﬂuxed for 24 h. The solid separated
upon evaporating the reaction mixture under reduced pressure
was collected, washed with water and crystallized from ethanol
affording the corresponding 9a,b.
2.1.6.1. 3-(4-Benzylidene-5-oxo-2-phenyl-4,5-dihydro-1H-imi-
dazol-1-yl)-6-iodo-2-(phenoxymethyl)quinazolin-4(3H)-one
(9a). Colorless crystals, mp 100–103 C, yield 30%. IR: mmax/
cm1 1693 (C‚O), 1556, 1591 (C‚C). 1H NMR (DMSO-d6):
d 5.09 (s, 2H, CH2), 7.04–8.51 (m, 18H, 15 arom. H + 3 qui-
nazolinone H), 9.95 (s, 1H, CH=C). MS: m/z (%): 624
(M+, 10.80), 261 (9), 245 (1), 215 (100). Anal. calcd. for
C31H21IN4O3 (624.43): C, 59.63; H, 3.39; N, 8.97. Found: C,
59.71; H, 3.45; N, 9.18.
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dro-1H-imidazol-1-yl)-6-iodo-2-(phenoxymethyl)quinazolin-
4(3H)-one (9b). Colorless crystals, mp 117–118 C, yield
35%. IR: mmax/cm
1 1697 (C‚O), 1558, 1593 (C‚C). 1H
NMR (DMSO-d6): d 5.06 (s, 2H, CH2), 6.72–8.46 (m, 17H,
14 arom. H + 3 quinazolinone H), 9.96 (s, 1H, CH=C).
MS: m/z (%): 660 (M+ 2, 13), 536 (6), 284 (48), 128 (100).
Anal. calcd. for C31H20ClIN4O3 (658.87): C, 56.51; H, 3.06;
N,8.50. Found: C, 56.49; H, 3.13; N, 8.72.
2.1.7. 2-Chloro-N-(6-iodo-4-oxo-2-(phenoxymethyl)quinazolin-
3(4H)-yl)acetamide (10)
A mixture of 4 (10 mmol, 4.6 g) and chloroacetyl chloride
(15 mmol, 1.6 g) in dimethylformamide (10 ml) was stirred
overnight at room temperature (20–25 C). The reaction
mixture was poured onto ice-cold water and the separated
solid was collected, dried and crystallized from ethanol.
Yellow crystals from ethanol, mp 120–122 C, yield 87%.
IR: mmax/cm
1 3483 (NH), 1716, 1689 (C‚O), 1589 (C‚C).
1H NMR (CDCl3): d 4.16 (d, 1H, upﬁeld H of COCH2,
J= 15.3), 4.30 (d, 1H, downﬁeld H of COCH2, J= 14.7),
5.00 (s, 2H, OCH2), 7.00–8.63 (m, 8H, 5 arom. H + 3 quinaz-
olinone H), 8.99 (s, 1H, D2O exchangeable NH). MS: m/z (%):
469 (M+, 30), 285 (5), 271 (32), 377 (100). 13C NMR (CDCl3):
40.9 (COCH2), 67.9 (OCH2), 92.7 (quinazolinyl C-6), 122.7
(quinazolinyl C-4a), 128.9 (quinazolinyl C-8) 135.7 (quinazoli-
nyl C-5), 143.9 (quinazolinyl C-7), 145.4 (quinazolinyl C-8a),
157.5 (quinazolinyl C-2), 162.0 (quinazolinyl C-4), 114.6,
122.0, 129.6, 152.3 (arom. C), 166.0 (C‚O). Anal. calcd. for
C17H13ClIN3O3 (469.66): C, 43.47; H, 2.79; N,8.95. Found:
C, 43.06; H, 2.37; N, 9.23.
2.1.8. General procedure for preparation of compounds 12a–c
A mixture of equimolar amounts of 10 and 2-amino-5-
(4(un)substituted phenyl)-1,3,4-oxa/thiadiazole 11a–c
(10 mmol) in acetonitrile (15 ml) containing anhydrous potas-
sium carbonate (15 mmol, 2 g), was reﬂuxed for 12 h. The
reaction mixture was poured onto ice-cold water. The sepa-
rated solid was collected, dried and crystallized from ethanol
to give the corresponding 12a–c.
2.1.8.1. 2-(5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-ylamino)-N-
(6-iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-yl)acetam-
ide (12a). Colorless crystals, mp 100–103 C, yield 40%. IR:
mmax/cm
1 3433, 3197 (NH), 1701 (C‚O), 1566, 1589
(C‚C). 1H NMR (CDCl3): d 4.65 (s, 2H, COCH2), 5.10 (s,
2H, OCH2), 5.20 (s, 1H, D2O exchangeable NHCH2), 7.03–
7.92 (m, 12H, 9 arom. H + 3 quinazolinone H), 7.92 (s, 1H,
D2O exchangeable NHCO). MS: m/z (%): 628 (M
+, 0.08),
421 (2), 195 (9), 180 (12), 138 (100). Anal. calcd. for
C25H18ClIN6O4 (628.81): C, 47.75; H, 2.89; N,13.37. Found:
C, 48.11; H, 2.97; N, 13.52.
2.1.8.2. N-(6-Iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-
yl)-2-(5-phenyl-1,3,4-thiadiazol-2-ylamino)acetamide (12b).
Colorless crystals, mp 163–165 C, yield 35%. IR: mmax/cm1
3178 (NH), 1678 (C‚O), 1570, 1597 (C‚C). 1H NMR
(DMSO-d6): d 4.70 (s, 2H, COCH2), 4.98 (s, 2H, OCH2),
6.97–8.38 (m, 15H, 11 arom. H + 3 quinazolinone
H + NHCH2), 12.60 (s, 1H, NHCO). MS: m/z (%): 610
(M+, 7), 285 (100), 272 (34), 177 (50). Anal. calcd. forC25H19IN6O3S (610.43): C, 49.19; H, 3.14; N, 13.77. Found:
C, 49.37; H, 3.30; N, 13.89.
2.1.8.3. 2-(5-(4-Chlorophenyl)-1,3,4-thiadiazol-2-ylamino)-N-
(6-iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-yl)acetam-
ide (12c). Colorless crystals, mp 176–179 C, yield 30%. IR:
mmax/cm
1 3182 (NH), 1681 (C‚O), 1535, 1597 (C‚C). 1H
NMR (DMSO-d6): d 4.99 (s, 2H, COCH2), 5.31 (s, 2H,
OCH2), 6.98–8.58 (m, 14H, 10 arom. H + 3 quinazolinone
H+ NHCH2), 12.65 (s, 1H, NHCO). MS: m/z (%): 643
(M-1, 6), 287 (15), 194 (31), 94 (100). Anal. calcd. for
C25H18ClIN6O3S (644.87): C, 46.56; H, 2.81; N, 13.03. Found:
C, 46.83; H, 2.98; N, 13.24.
2.1.9. General procedure for preparation of compounds 13a–c
A mixture of equimolar amounts of 10 and the appropriate
sulfonamide (10 mmol) in acetonitrile (15 ml) containing anhy-
drous potassium carbonate (15 mmol, 2 g), was reﬂuxed for
12 h. The reaction mixture was poured onto ice-cold water.
The separated solid was collected, dried and crystallized from
ethanol to yield the corresponding 13a–c.
2.1.9.1. N-(6-Iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-
yl)-2-(4-sulfamoylphenylamino)acetamide (13a). Yellow crys-
tals, mp 148–149 C, yield 40%. IR: mmax/cm1 3468, 3356,
3221 (NH), 1685 (C‚O), 1597 (C‚C). 1H NMR (CDCl3): d
3.50 (s, 2H, COCH2), 5.06 (s, 2H, OCH2), 7.00 (s, 1H, D2O
exchangeable NHCH2), 7.38 (s, 2H, D2O exchangeable
NH2), 7.02–8.64 (m, 12H, 9 arom. H + 3 quinazolinone H),
9.60 (s, 1H, D2O exchangeable NHCO). MS: m/z (%): 607
(M+ 2, 0.57), 285 (4), 169 (3), 65 (100). Anal. calcd. for
C23H20IN5O5S (605.40): C, 45.63; H, 3.33; N,11.57. Found:
C, 45.75; H, 3.37; N, 11.78.
2.1.9.2. 2-(4-(N-Carbamimidoylsulfamoyl)phenylamino)-N-(6-
iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-yl)acetamide
(13b). Colorless crystals, mp 88–90 C, yield 45%. IR: mmax/
cm1 3483, 3313, 3201 (NH), 1689 (C‚O), 1554, 1597
(C‚C). 1H NMR (CDCl3): d 4.19 (s, 2H, COCH2), 5.06 (s,
2H, OCH2), 5.28 (s, 1H, D2O exchangeable NHCH2), 5.31
(s, 1H, D2O exchangeable NH of C = NH), 7.00 (s, 2H,
D2O exchangeable NH2), 7.03–8.59 (m, 12H, 9 arom. H + 3
quinazolinone H), 8.60 (s, 1H, D2O exchangeable NHCO),
8.80 (s, 1H, D2O exchangeable NHSO2). MS: m/z (%): 647
(M+, 16), 256 (53), 213 (33), 60 (100). 13C NMR (CDCl3):
41.0 (COCH2), 67.9 (OCH2), 92.7 (quinazolinyl C-6), 122.7
(quinazolinyl C-4a),129.4 (quinazolinyl C-8), 135.2 (quinazoli-
nyl C-5), 143.0 (quinazolinyl C-7), 145.4 (quinazolinyl C-8a),
157.5 (quinazolinyl C-2), 157.8 (quinazolinyl C-4), 114.6,
122.0, 129.59, 129.6, 129.7, 135.8, 143.9, 152.2 (arom. C),
158.0 (guanidino-C), 165.5 (C‚O). Anal. Calcd. for C24H22I-
N7O5S (647.44): C, 44.52; H, 3.42; N,15.14. Found: C, 44.63;
H, 3.39; N, 15.61.
2.1.9.3. N-(6-Iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-
yl)-2-(4-(N-pyridin-2-ylsulfamoyl)phenylamino)acetamide
(13c). Buff crystals, mp 190–192 C, yield 40%. IR: mmax/cm1
3448, 3371 (NH), 1732 (C‚O), 1554, 1597 (C‚C). 1H NMR
(DMSO-d6): d 5.11 (s, 2H, COCH2), 5.27 (s, 2H, OCH2), 5.69
(s, 1H, D2O exchangeable NHCH2), 6.41–8.14 (m, 18H, 13
arom. H + 3 quinazolinone H+ NHSO2 + NHCO). MS:
280 S.E. Abbas et al.m/z (%): 683 (M+ 1, 1), 258 (1), 158 (1), 65 (100). Anal.
calcd. for C28H23IN6O5S (682.49): C, 49.28; H, 3.40; N,
12.31. Found: C, 49.52; H, 3.48; N, 12.73.
2.1.10. General procedure for preparation of compounds 14a–c
A mixture of equimolar amounts of 10 and the appropriate
piperidine (10 mmol) in acetonitrile (15 ml) containing 5 drops
of triethylamine, was reﬂuxed for 12 h. The reaction mixture
was ﬁltered while hot and the clear solution was evaporated
under reduced pressure. The remaining residue was collected,
washed with water and crystallized from ethanol affording
the corresponding 14a–c.
2.1.10.1. N-(6-Iodo-4-oxo-2-(phenoxymethyl)quinazolin-
3(4H)-yl)-2-(piperidin-1-yl)acetamide (14a). Buff crystals,
mp 180–181 C, yield 40%. IR: mmax/cm1 3205 (NH), 1728,
1701 (C‚O), 1589 (C‚C). 1H NMR (DMSO-d6): d 1.35–
1.64 (m, 10H, piperidinyl H), 3.21 (s, 2H, COCH2), 5.06 (s,
2H, OCH2), 6.39–8.42 (m, 8H, 5 arom. H + 3 quinazolinone
H), 8.42 (s, 1H, D2O exchangeable NH). MS: m/z (%): 519
(M+ 1, 23), 141 (46), 87 (65), 73 (100). Anal. calcd. for
C22H23IN4O3 (518.35): C, 50.98; H, 4.47; N, 10.81. Found:
C, 51.07; H, 4.53; N, 11.15.
2.1.10.2. N-(6-Iodo-4-oxo-2-(phenoxymethyl)quinazolin-
3(4H)-yl)-2-(4-phenylpiperidin-1-yl)acetamide (14b). Buff
crystals, mp 85–88 C, yield 45%. IR: mmax/cm1 3313 (NH),
1670, 1635 (C‚O), 1589 (C‚C). 1H NMR (CDCl3): d 1.82–
2.67 (m, 9H, piperidinyl H), 3.33 (s, 2H, COCH2), 5.30 (s,
2H, OCH2), 7.00–8.64 (m, 13H, 10 arom. H + 3 quinazoli-
none H), 8.63 (s, 1H, D2O exchangeable NH). MS: m/z (%):
593 (M-1, 0.06), 285 (4), 160 (3), 174 (100). Anal. calcd. for
C28H27IN4O3 (594.44): C, 56.57; H, 4.58; N,9.43. Found: C,
56.64; H, 4.61; N, 9.63.
2.1.10.3. 2-(4-Hydroxy-4-phenylpiperidin-1-yl)-N-(6-iodo-4-
oxo-2-(phenoxymethyl) quinazolin-3(4H)-yl)acetamide (14c).
Buff crystals, mp 85–88 C, yield 45%. IR: mmax/cm1 3504
(OH), 3385 (NH), 1718, 1685 (C‚O), 1588 (C‚C). 1H
NMR (CDCl3): d 1.70–2.83 (m, 8H, piperidinyl H), 3.14 (s,
1H, D2O exchangeable OH), 3.38 (s, 2H, COCH2), 5.02 (s,
2H, OCH2), 6.95–8.58 (m, 13H, 10 arom. H + 3 quinazoli-
none H), 8.06 (s, 1H, D2O exchangeable NH). MS: m/z (%):
611 (M+ 1, 0.14), 285 (100), 232 (9). Anal. Calcd. for
C28H27IN4O4 (610.44): C, 55.09; H, 4.46; N,9.18. Found: C,
55.13; H, 4.52; N, 9.34.
2.1.11. 2-(6-Iodo-4-oxo-2-(phenoxymethyl)quinazolin-3(4H)-
ylamino)thiazol-4(5H)-one (15)
A mixture of equimolar amounts of 10 and ammonium thiocy-
anate (10 mmol) in absolute ethanol (20 ml) was reﬂuxed for
8 h. The reaction mixture was ﬁltered while hot. The solid sep-
arated upon storing the clear reaction mixture at room temper-
ature overnight was collected, dried and crystallized from
ethanol.
Colorless crystals, mp 165–166 C, yield 50%. IR: mmax/cm1
3313 (NH), 1743, 1651 (C‚O), 1560, 1585 (C‚C). 1H
NMR (DMSO-d6): d 4.08 (s, 2H, COCH2), 5.32 (s, 2H,
OCH2), 6.93–8.42 (m, 8H, 5 arom. H + 3 quinazolinone H),
12.45 (s, 1H, D2O exchangeable NH). MS: m/z (%): 492
(M+, 31), 491 (100), 418 (24), 285 (44). 13C NMR (DMSO-d6): 38.6 (thiazolo-CH2), 66.1 (OCH2), 91.6 (quinazolinyl C-
6), 122.1 (quinazolinyl C-4a), 129.3 (quinazolinyl C-8), 134.0
(quinazolinyl C-5), 142.5 (quinazolinyl C-7), 145.5 (quinazoli-
nyl C-8a), 154.0 (quinazolinyl C-2), 158.1 (thiazolo C‚N),
159.2 (thiazolo CO), 162.1 (quinazolinyl C-4), 114.6, 120.9,
129.4, 146.0 (arom. C). Anal. calcd. for C18H13IN4O3S
(492.29): C, 43.92; H, 2.66; N,11.38; S, 6.51. Found: C,
44.10; H, 2.71; N, 11.52 ; S, 6.62.
2.1.12. 10-Iodo-6-(phenoxymethyl)-2H-[1,2,4]triazino[2,3-
c]quinazolin-3(4H)-one (16)
A mixture of equimolar amounts of 10 and ammonium acetate
(10 mmol) in glacial acetic acid (15 ml) was reﬂuxed for 3 h.
The reaction mixture was then poured onto ice-cold water.
The separated solid was collected, washed with water, dried
and crystallized from ethanol.
Colorless crystals, mp 140–141 C, yield 60%. IR: mmax/cm1
3194 (NH), 1681(C‚O), 1593, 1562 (C‚C). 1H NMR
(DMSO-d6): d 4.75 (s, 2H, OCH2), 5.07 (s, 2H, COCH2),
6.92–8.42 (m, 8H, 5 arom. H + 3 quinazolinone H), 12.65 (s,
1H, D2O exchangeable NH). MS: m/z (%): 435 (M+ 3, 2),
376 (47), 328 (2), 77 (100). 13C NMR (DMSO-d6): 40.6 (triaz-
ino-CH2), 67.4 (OCH2), 91.0 (quinazolinyl C-6), 121.5 (quinaz-
olinyl C-4a), 129.3 (quinazolinyl C-8), 134.6 (quinazolinyl C-
5), 142.8 (quinazolinyl C-7), 143.6 (quinazolinyl C-8a), 157.5
(quinazolinyl C-2), 157.7 (quinazolinyl C-4), 207.7 (triazino
CO), 114.7, 121.3, 129.4, 146.0 (arom. C). Anal. calcd. for
C17H13IN4O2 (432.22): C, 47.27; H, 3.03; N,12.96. Found: C,
47.37; H, 3.12; N, 13.31.
2.1.13. 12-Iodo-8-(phenoxymethyl)-2-thioxo-3,4-dihydro-2H-
[1,2,4,6]tetrazocino[2,3-c]quinazolin-5(6H)-one (17)
A mixture of equimolar amounts of 10 and thiourea (10 mmol)
in absolute ethanol (20 ml) was reﬂuxed for 8 h. The solid sep-
arated upon evaporating the reaction mixture under reduced
pressure was collected, washed with water and crystallized
from ethanol.
Buff crystals, mp 135–138 C, yield 50%. IR: mmax/cm1
3367, 3167 (NH), 1681 (C‚O), 1597 (C‚C). 1H NMR
(DMSO-d6): d 2.08 (s, 2H, COCH2), 5.04 (s, 2H, OCH2),
6.96–8.47 (m, 8H, 5 arom. H + 3 quinazolinone H), 11.19 (s,
2H, D2O exchangeable NHs). MS: m/z (%): 492 (M+ 1,
17), 393 (22), 342 (100), 285 (6). 13C NMR (DMSO-d6): 21.2
(tetrazocino-CH2), 67.4 (OCH2), 94.0 (quinazolinyl C-6),
122.0 (quinazolinyl C-4a), 129.5 (quinazolinyl C-8), 135.0 (qui-
nazolinyl C-5), 144.4 (quinazolinyl C-7), 145.0 (quinazolinyl
C-8a), 157.2 (quinazolinyl C-2), 157.6 (quinazolinyl C-4),
170.2 (tetrazocino CO), 171.0 (tetrazocino CS), 114.4, 121.6,
129.9, 146.0 (arom. C). Anal. calcd. for C18H14IN5O2S
(491.31): C, 44.00; H, 2.87; N, 14.25. Found: C, 43.95; H,
2.93; N, 14.44.3. Antitumor activity screening
The screening involves calculation of the percentage growth of
surviving fraction of the drug treated cell lines compared by
untreated control using Sulforhodamine B (SRB) colorimetric
assay. Sulforhodamine B is a bright pink aminoxanthene anio-
nic dye with two sulfonic acid groups that bind electrostati-
cally to protein basic amino acid residues of trichloroacetic
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tures ﬁxed with trichloroacetic acid were stained for 30 min
with 0.4% w/v Sulforhodamine B dissolved in 1% acetic acid,
and protein-bound dye was extracted with 10 mM tris base for
determination of optical density in a computer-interfaced, 96-
well microtiter plate reader.
The optical density measured is linear to the cell number of
the surviving fraction. Therefore, the assay is a sensitive mea-
sure of drug induced cytotoxicity with the best signal to noise
ratio. The assay also, provides a colorimetric end point that is
nondestructive, indeﬁnitely stable and visible to naked eye.
Cells were plated in 96-muliwell plate (104 cells/well) for
24 h. before treatment with the compounds to allow attach-
ment of cell to the wall of the plate. Different concentrations
of the compound under test (0, 1, 2.5, 5 and 10 lg/ml) were
added to the cell monolayer. Triplicate wells were prepared
for each individual dose. Monolayer cells were then incubated
with the compound for 48 h at 37 C and in atmosphere of 5%
CO2. After this time, cells were ﬁxed, washed and stained with
Sulforhodamine B stain. Excess stain was washed with acetic
acid and attached stain was recovered with Tris EDTA buffer.
The color intensity was measured in an ELISA reader. Finally,
the relation between surviving fraction and drug concentration
was plotted to get the survival curve of the tumor cell line after
the speciﬁc compound.
Screening of the antitumor activity of the synthesized com-
pounds against MCF-7 cell line was determined using Sulfo-
rhodamine-B assay. From the obtained results (Table 1), it
has been observed that several newly prepared compounds ex-
hibit a considerable antitumor activity especially 5b, 6c, 7d andTable 1 Antitumor activity of the newly synthesized
compounds.
Compound IC50 lmol/ml
4 24.92
5a 21.59
5b 5.49
5c 27.51
6a 13.29
6b 8.14
6c 6.80
6d 19.55
7a 15.31
7b 28.58
7c 42.69
7d 6.23
9a 16.01
9b 17.03
10 24.27
12a 8.58
12b 6.55
12c 11.47
13a 7.59
13b 8.95
13c 16.99
14a 37.81
14b 22.54
14c 28.50
15 21.53
16 10.18
17 8.14
Doxorubicin 5.4612b which reveal remarkable activities with IC50 5.49, 6.80,
6.23 and 6.55 lmol/ml, respectively comparable to that of
Doxorubicin (IC50: 5.46 lmol/ml) which was used as a refer-
ence standard.
The structure–activity relationship study based on the ob-
served results indicated that, blocking the amino group of
the key intermediate 4 (IC50: 24.92 lmol/ml) by acylation as
exhibited in 5a,b (IC50: 21.59, 5.49 lmol/ml), condensation
with aldehydes 6a–d (IC50: 6.80–19.55 lmol/ml) or by reaction
with phenyl oxazolone derivatives 9a,b (IC50: 16.01,
17.03 lmol/ml), increase the antitumor activity.
Concerning the activity of benzylideneamino derivatives
6a–d, the type of aryl substitution plays a controlling role for
developing the exhibited pharmacological properties. It has
been noticed that, substitution on the phenyl group with an
electron-withdrawing group such as a chlorine or a ﬂuorine
atom 6b,c (IC50: 8.14, 6.80 lmol/ml) seems more favorable
for enhancing the antitumor activity than the unsubstituted
phenyl ring 6a (IC50: 13.29 lmol/ml) or the substitution with
an electron-donating group such as methoxy residue 6d
(IC50: 19.55 lmol/ml). However, comparing the antitumor
activity of 6a–d relative to their reduced products 7a–d, a
remarkable decrease in the antitumor activity was observed
as exhibited in compounds 7a–c (IC50: 15.30, 28.5 and
42.6 lmol/ml, respectively), except with the electron-donating
substitution 7d, that exhibited a prominent increase in the
activity (IC50: 6.23 lmol/ml).
Meanwhile, it was found that adopting an iodo substituent
at the 6-position of the quinazolinone core showed a slight in-
crease in the antitumor activity as represented in compound 10
(IC50: 24.27 lmol/ml), compared to the reported non-iodin-
ated derivative which was completely inactive.13
However, nucleophilic substitution of the chloroacetylami-
no derivative 10 (IC50: 24.27 lmol/ml) with amino-oxa/thiadi-
azole moieties or various sulfonamides afforded 12a–c and
13a–c. The obtained data showed a remarkable increase in
the antitumor activity (IC50: 8.58, 6.55 and 11.47 lmol/ml)
and (IC50: 7.59, 8.95 and 16.99 lmol/ml, respectively).
Whereas, the antitumor activity decreased by nucleophilic sub-
stitution with secondary amines (piperidinyl residue) as shown
in compounds 14a and c (IC50: 28.50 and 37.81 lmol/ml).
Cyclization of the chloroacetylamino derivative 10 (IC50:
24.27 lmol/ml) to a thiazolone derivative 15 (IC50:
21.53 lmol/ml) exhibited a slight increase in the antitumor
activity. Rigidiﬁcation of the chloroacetylamino derivative 10
(IC50: 24.27 lmol/ml) into a triazino derivative 16 (IC50:
10.18 lmol/ml) led to a sharp increase in the antitumor activ-
ity. Ring expansion of triazino to tetrazocino derivative 17 en-
hanced the antitumor activity as expressed by its IC50 value
(IC50: 8.14 lmol/ml).
4. Conclusion
The most potent compound was the pyrrole-2,5-dione deriva-
tive 5b (IC50: 5.49 lmol/ml) which showed nearly an equipo-
tent activity to that of Doxorubicin (IC50: 5.46 lmol/ml).
Moreover, eight compounds exhibited a remarkable antitumor
activity: the reduced Schiff’s base (4-methoxy benzylamino
derivative) 7d, 5-phenyl-1,3,4-thiadiazolo derivative 12b,
Schiff’s derivative (4-ﬂuoro benzylideneamino) 6c, sulfamoyl
phenylamino derivative 13a, 4-chlorobenzylidene amino
282 S.E. Abbas et al.derivative 6b, tetrazocino derivative 17, 5-(4-chlorophenyl)-
1,3,4-oxadiazolo derivative 12a and carbamimidoyl sulfamoyl
phenylamino derivative 13b (IC50: 6.23, 6.55, 6.80, 7.59, 8.14,
8.14, 8.58 and 8.95 lmol/ml, respectively).
Additionally, three compounds revealed a moderate antitu-
mor activity: triazino derivative 16, 5-(4-chlorophenyl)-1,3,
4-thiadiazolo derivative 12c and benzylideneamino 6a (IC50:
10.18, 11.47 and 13.29 lmol/ml, respectively).
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Thanks are due to the National Cancer Institute, Cairo Uni-
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compounds.
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